AI assistant
Marksans Pharma Ltd. — Earnings Release 2019
Feb 8, 2019
62142_rns_2019-02-08_b95bf27c-3691-4aef-bda2-12beac95fead.pdf
Earnings Release
Open in viewerOpens in your device viewer
·t· Marksans Pharma Ltd.
BSELimited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404
National Stock Exchange of India Limited listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS
Enclosed herewith kindly find a News Release dated 8[th] February, 2019 of the Company.
Yours faithfully, For Marksans Pharma Limited -- ~Jt Harshavardhan Panigrahi Company Secretary & Manager - Legal
Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • E-mail: [email protected] www.marksanspharma.com
.-. Marksans Pharma Ltd.
NEWS RELEASE 8[th] February 2019, Mumbai - India
Marksans Pharma Limited has reported today its Fianancial Performance for the 03 FY 2018-19 and for the Nine months period ended 31[st] December 2018
-
EBITDA increase by 319 basis points
-
Profit after Tax was Rs.70.59 crores for the period as compared to Rs.42.28 crores during previous period ,registering growth of 66.96%
-
EBITDA was Rs.111.38 crores for the period as compared to Rs.82.86 crores during previous period, registering growth of 34.42%
-
Consolidated EBITDA increased by 319 basis points from 11.61% to 14.80% during the period.
-
Consolidated Revenue at Rs.752.84 crores in Nine months of FY 2018-19 as compared to Rs. 713. 73 crores during previous period, registering growth of 5.48%.
-
Net Profit After Tax for the quarter was at Rs.25.13 Crores, as compared to Rs.17.46 crores during previous period ,registering growth of 43.93%
-
EBITDA for the quarter was at Rs.36.34 crores as compared to Rs.29.24 crores during previous period ,registering growth of 24.28%
-
Consolidated Revenue was at Rs.248.52 Crore as compared to Rs.218.82 crores during previous period ,registering growth of 13.57%
·4· Marksans Pharma Ltd.
evenue IQ"uresonso I ate
| evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate | evenueIQ"ures-onso I ate |
|---|---|---|---|---|---|---|---|
| INR in crores | |||||||
| First Ni | ne MonthsofFY 2018-19 | ||||||
| FY | FY | Growth% | Mix% | ||||
| 2018-19 | 2017-18 | ||||||
| Europe, UK - FormulationsUS &North America-FormulationsAustralia &NZ - FormulationsRest ofWorld(ROW) | 323.14309.3079.4040.99 | 328.23281.9374.9528.62 | -1.55%9.71%5.94%43.22% | 42.92%41.09%10.55%5.44% | |||
| lif | 548% | ||||||
| Consodated Revenue romoperations | 752.84 | 713.73 | . | 100.00% | |||
-
Europe, UK Formulation business revenue was at Rs.323.14 crores as compared to Rs.328.23 crores achieved during previous year same period.
-
US & North America Formulation business reported revenue of Rs.309.30 crores as against revenue of Rs.281.93 crores achieved during last year, registering growth of9.71%.
-
Australia & NZ Formulation business revenue was at Rs. 79.40 crores as compared Rs.74.95 crores achieved during previous year same period.
-
Rest of World Formulation business was Rs.40.99 crores as compared to Rs.28.62 crores achieved during last year same period, registering growth of 43.22%.
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including UK MHRA,US FDA & Australia TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The company is marketing these products ' .~ W
globally.
~ a spharma.com
CIN : L24110MH1992PLC066364
••
Marksans Pharma Ltd.
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results' of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Marksans may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
MarksansPharmaLimited Il[th] Floor, "GRANDEUR",VeeradesaiExtensionRoad, Oshiwara,Andheri- (West),Mumbai- 400053, India Tel:- +91 224001 2000,Fax:-+91 224001 2011.